This inventor holds 39 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 13 EPO patents, primarily in Hepatitis C Treatment. Top assignees: Bristol-Myers Squibb Compnay, Ptc Therapeutics, Inc., Syntex (u.s.a.) Inc.. Active years: 1996-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Rutland, VT (US) (1996)
- Fremont, CA (US) (1999 - 2005)
- Royal Oak, MI (US) (2007)
- Cheshire, CT (US) (2002 - 2008)
- Glen Gardner, NJ (US) (2006 - 2011)
- Hilton Head Island, SC (US) (2016)
- Bethlehem, PA (US) (2010 - 2017)
Company Filing History:
11 out of 3,742 
11 out of 186 
11 out of 932 
Years Active: 1996-2017
Areas of Expertise:
Title: Innovations and Contributions of Jeffrey Allen Campbell
Introduction
Jeffrey Allen Campbell, a prolific inventor based in Cheshire, Connecticut, holds an impressive portfolio of 39 patents. His work primarily focuses on advancing healthcare through groundbreaking inventions aimed at treating diseases caused by nonsense mutations in mRNA, as well as those targeting cancer and viral infections.
Latest Patents
Among Campbell's latest innovations are significant advancements in 1,3,4-oxadiazole benzoic acid compounds. These compounds are essential for suppressing nonsense mutations that lead to premature translation termination in mRNA, paving the way for treatments aimed at various diseases. Furthermore, his research has led to the development of methods and compounds that selectively inhibit the pathological production of human vascular endothelial growth factor (VEGF), instrumental in tackling both cancer and non-neoplastic conditions. Additionally, his inventions include compounds designed to inhibit viral replication, which may offer new avenues for treating viral infections. These compounds are adaptable for use as standalone therapies or in combination with other treatments.
Career Highlights
Jeffrey Allen Campbell has built a robust career through his associations with renowned companies in the pharmaceutical sector. He has contributed significantly to Bristol-Myers Squibb Company and Syntex (U.S.A.) Inc., where his work on innovative compounds has had a lasting impact on drug development and therapeutic strategies.
Collaborations
Throughout his career, Campbell has worked alongside notable colleagues such as Chris Allen Broka and Andrew Charles Good. These collaborations have fostered a creative environment that has been crucial in advancing their shared goals in pharmaceutical innovations and inventions.
Conclusion
In summary, Jeffrey Allen Campbell stands out as a distinguished inventor with a track record of impactful contributions to the field of medicine. With his 39 patents, his innovations continue to inspire future developments aimed at addressing complex health challenges, marking him as a significant figure in the realm of biotechnology and pharmaceuticals.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile